SILENCE THERAP. SP.ADR/1 (F:XRP2) — Stock Price
SILENCE THERAP. SP.ADR/1 (F:XRP2) is currently trading at €7.00 EUR, up 10.24% today. Over the past 52 weeks, shares have ranged between €2.70 and €7.00. This page tracks SILENCE THERAP. SP.ADR/1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of SILENCE THERAP. SP.ADR/1.
SILENCE THERAP. SP.ADR/1 (XRP2) Stock Price Chart — Daily History & Trading Volume
The chart below tracks SILENCE THERAP. SP.ADR/1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
SILENCE THERAP. SP.ADR/1 Income Statement — Revenue, Profit & Earnings by Year
SILENCE THERAP. SP.ADR/1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €559.00K | €43.26 Million | €31.64 Million | €21.66 Million | €16.76 Million |
| Cost of Revenue | €215.00K | €11.81 Million | €12.87 Million | €13.46 Million | €10.06 Million |
| Gross Profit | €344.00K | €31.45 Million | €18.78 Million | €8.19 Million | €6.69 Million |
| Research & Development | €67.75 Million | €67.88 Million | €56.94 Million | €43.55 Million | €41.52 Million |
| SG&A | €22.34 Million | €26.88 Million | €26.22 Million | €25.68 Million | €27.00 Million |
| Total Operating Expenses | €90.31 Million | €106.58 Million | €96.03 Million | €82.69 Million | €78.59 Million |
| Operating Income | €-89.75 Million | €-63.32 Million | €-64.38 Million | €-61.04 Million | €-61.83 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | — | — | €43.31K | €56.88K | €10.80K |
| Income Before Tax | €-88.60 Million | €-44.46 Million | €-53.27 Million | €-49.65 Million | €-61.89 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-88.61 Million | €-45.31 Million | €-54.23 Million | €-50.33 Million | €-53.19 Million |
SILENCE THERAP. SP.ADR/1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes SILENCE THERAP. SP.ADR/1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €131.44 Million | €202.63 Million | €119.45 Million | €130.10 Million | €129.83 Million |
| Total Current Assets | €118.66 Million | €187.37 Million | €103.15 Million | €117.01 Million | €116.52 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €73.84 Million | €26.00 Million | €0.00 | €19.76 Million | €0.00 |
| Net Receivables | €0.00 | €972.00K | €290.00K | €1.11 Million | €446.73K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €10.62 Million | €9.39 Million | €9.98 Million | €9.69 Million | €10.25 Million |
| Total Liabilities | €69.14 Million | €68.61 Million | €97.45 Million | €103.38 Million | €118.32 Million |
| Total Current Liabilities | €13.61 Million | €16.82 Million | €22.34 Million | €26.56 Million | €20.47 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €62.30 Million | €134.02 Million | €21.99 Million | €26.71 Million | €11.51 Million |
| Retained Earnings | €-562.57 Million | €-474.04 Million | €-431.89 Million | €-318.60 Million | €-300.92 Million |
SILENCE THERAP. SP.ADR/1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how SILENCE THERAP. SP.ADR/1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-62.27 Million | €-67.64 Million | €-49.46 Million | €-57.04 Million | €9.19 Million |
| Capital Expenditures | €55.00K | €211.00K | €56.00K | €545.00K | €1.80 Million |
| Free Cash Flow | €-62.33 Million | €-67.85 Million | €-49.52 Million | €-57.59 Million | €7.39 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €15.00K | €142.09 Million | €31.94 Million | €52.58 Million | €41.45 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €8.07 Million | €16.31 Million | €16.27 Million | €12.69 Million | €11.65 Million |
| Depreciation | €555.00K | €593.00K | €621.00K | €596.00K | €576.29K |
| Change in Cash | €-110.25 Million | €52.48 Million | €1.77 Million | €-24.96 Million | €62.34 Million |
SILENCE THERAP. SP.ADR/1 Earnings History — EPS Actual vs. Analyst Estimates
Track SILENCE THERAP. SP.ADR/1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | -0.11 | — |
| May 07, 2026 | — | -0.18 | — |
| Feb 26, 2026 | — | -0.49 | — |
| Nov 13, 2025 | — | -0.21 | — |
| May 16, 2025 | — | — | — |